Marvell’s management just handed Wall Street a revenue target so far above analyst models that the stock surged double digits, yet one key risk could make the whole thesis collapse before the decade ends.
A 26% price drop on a stock with a near-monopoly business model and 85% recurring revenue sounds like a warning, but one investor sees it as an invitation to keep buying.
Cisco just posted its fifth straight earnings beat while AI infrastructure orders piled up, but the real question is whether the valuation still leaves room to run or whether this rally has already priced in the upside.
Coca-Cola just posted its best volume growth in nearly two decades, raised guidance twice, and beat earnings six quarters straight. So why do the numbers suggest investors may already be paying too much for that track record?
Pfizer’s yield towers over Johnson and Johnson’s, but a bigger number on paper can hide serious risks underneath. Before you chase that payout, consider what a frozen dividend, rising debt, and a multibillion-dollar write-down actually signal about income reliability.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
Strategy Inc. lost more than half its value while quietly becoming the world’s largest corporate Bitcoin treasury, and one Wall Street analyst thinks that combination sets up a trade most investors are too spooked to touch.
A struggling PC maker quietly reinvented itself around AI servers, and investors who held through two brutal drawdowns collected returns that left the S&P 500 in the dust. The question now is whether Dell has already peaked or is still early.
Iambic sets $15-$17 range for $150 million Nasdaq IPO
Iambic Therapeutics put a price on its Nasdaq debut, about $150 million raised at $15 to $17 per share. Pricing is the last step before the AI drug discovery name starts trading.
Source: SEC filingBrewDog lifted beverage revenue 82% to $101.5 million, yet both EPS and revenue missed expectations. Management reaffirmed fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million, leaning on second-half seasonality and the Carlsberg US launch in January.
A $0 monthly premium sounds like free coverage until you read the pages most people skip. One number buried in the Annual Notice of Change quietly decides how much a serious diagnosis will actually cost in 2027.
A retiree exercised a stock option after leaving work and watched his W-2 balloon with what looked like fresh wages, threatening thousands in withheld Social Security benefits. Whether that money actually counts against him depends on a little-known IRS rule most payroll departm…
Trump once dismissed Camp David as a place you’d enjoy for about 30 minutes. Now a proposal sitting before Palm Beach County commissioners could permanently reshape where American presidents go to govern and host the world’s most powerful leaders.
